Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Dose-Response Effect of Intra-Articular Ozone in Knee Osteoarthritis

30 juin 2026 mis à jour par: Fatma Gül Ülkü Demir, Kayseri City Hospital

Dose-Response Effect of Intra-Articular Ozone in Knee Osteoarthritis: A Randomized Controlled Single-Blind Clinical Study

The goal of this clinical trial is to evaluate the clinical efficacy of different doses of intra-articular ozone injections combined with exercise in patients aged 40-75 diagnosed with Grade 2-3 knee osteoarthritis.

The main questions it aims to answer are:

  • Which intra-articular ozone doses (10 µg/mL, 15 µg/mL, or 20 µg/mL) is most effective in improving pain and physical function in knee osteoarthritis?
  • Do combined ozone and exercise therapies provide superior clinical outcomes compared to exercise therapy alone? Researchers will compare four groups (Ozone 10 µg/mL + Exercise, Ozone 15 µg/mL + Exercise, Ozone 20 µg/mL + Exercise and Exercise Alone) to see the dose-dependent effects of ozone therapy.

Participants will:

  • Complete a structured home exercise program for the duration of the study.
  • Receive 3 sessions of intra-articular ozone injections (for patients allocated to the ozone groups).
  • Participate follow-up visits for clinical and functional assessments at baseline (before the procedure), immediately after the 3rd injection session, at 1 month after the last ozone injection, and at 3 months after the last ozone injection.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This clinical trial is designed as a prospective, randomized, controlled study to investigate the dose-dependent therapeutic effects of intra-articular ozone therapy in patients with Grade 2-3 knee osteoarthritis.

Eligible participants aged 40-75 with a confirmed diagnosis of knee osteoarthritis (Kellgren-Lawrence Grade 2 or 3) will be recruited. Participants will be allocated into one of four parallel groups by computerized randomization.

All patients allocated to the ozone intervention groups will receive a total of 3 sessions of intra-articular ozone injections, administered once a week for three consecutive weeks. For all three treatment groups, the injection volume will be at 10 mL per session, while the ozone concentrations will vary according to the assigned group as follows:

Ozone 10 µg + Exercise: 10 mL of ozone injection at a concentration of 10 µg/mL + Home exercise program.

Ozone 15 µg + Exercise: 10 mL of ozone injection at a concentration of 15 µg/mL + Home exercise program.

Ozone 20 µg + Exercise: 10 mL of ozone injection at a concentration of 20 µg/mL + Home exercise program.

Exercise Alone (Control): Home exercise program alone.

All participants across all four groups will be prescribed a structured home exercise program. This program includes joint range of motion (ROM) exercises; strengthening exercises and flexibility exercises.

The home program will be performed for 30 minutes per day, 5 days a week, throughout the 3-month study period. To improve patient adherence to exercise, patients will be provided with an exercise diary and also an analgesic diary to track analgesic use.

Clinical and functional evaluations will be performed at four distinct time points: baseline (pre-treatment), immediately after the 3rd injection session (post-treatment), 1 month after the last ozone injection, and 3 months after the last ozone injection. The clinical and functional status of the participants will be evaluated using the Numerical Rating Scale (NRS) for pain severity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for knee-specific symptoms and physical function, the Lequesne Algofunctional Index for osteoarthritis severity and physical disability, and the EuroQol 5-Dimension (EQ-5D) questionnaire for overall health-related quality of life. Additionally, objective functional capacity, dynamic balance, and mobility will be assessed using the 6-Minute Walk Test (6MWT) and the Timed Up and Go (TUG) test.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

  • Turquie (Türkiye)
      • Kayseri, Turquie (Türkiye), 38080
        • Recrutement
        • Kayseri City Hospital
        • Contact:
        • Sous-enquêteur:
          • Serhat Efdal Ozbek, MD
        • Chercheur principal:
          • Fatma Gul Ulku Demir, MD
        • Sous-enquêteur:
          • Havva Talay Calis, Professor

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Patients aged 40-75 years diagnosed with knee osteoarthritis according to the American College of Rheumatology 2019 criteria
  • Grade 2 or 3 knee osteoarthritis based on the Kellgren-Lawrence radiological classification system.
  • Presence of chronic knee pain lasting for more than 6 months.
  • Numerical Rating Scale score of 3 or higher during knee-loading activities

Exclusion Criteria:

  • Presence or history of acute knee infection, major knee trauma, or inflammatory arthritis
  • History of knee fracture or surgical intervention involving the affected knee joint within the last 6 months.
  • History of intra-articular injections (e.g., corticosteroids, hyaluronic acid, PRP) into the affected knee joint within the last 6 months.
  • History of physical therapy or rehabilitation in the knee region within the last 6 months
  • Presence of osteomyelitis adjacent to the knee joint, bacteremia, or hemarthrosis.
  • History of malignancy involving the lower extremity.
  • Known hypersensitivity or allergy to medical ozone.
  • Severe anemia, thrombocytopenia, active bleeding disorders, or ongoing anticoagulant therapy.
  • Pregnancy or lactation
  • Active infection
  • Severe systemic diseases (e.g., advanced cardiopulmonary disease, uncontrolled diabetes mellitus).
  • Hyperthyroidism or progressive neuromuscular disorders.
  • Cognitive impairment or inability to cooperate with the assessment tools and study protocol.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: 10 µg Ozone + Exercise
10 mL of ozone injection at a concentration of 10 µg/mL + Home exercise program
Autre: ozone injection
All patients allocated to the ozone intervention groups will receive a total of 3 sessions of intra-articular ozone injections, administered once a week for three consecutive weeks. For all three treatment groups, the injection volume will be 10 mL per session, while the ozone concentrations will vary according to the assigned group as Ozone 10 µg/mL + Exercise, Ozone 15 µg/mL + Exercise, and Ozone 20 µg/mL + Exercise.
Autres noms:
  • Intra-articular Ozone Injection
Comportemental: Exercise

All participants across all four groups will be prescribed a structured home exercise program. This program includes joint range of motion (ROM) exercises; strengthening exercises (including quadriceps strengthening, hamstring strengthening, hip abductor strengthening, and seated calf raises); and flexibility exercises (including hamstring stretching, gastrocnemius-soleus stretching, and quadriceps stretching).

The home program will be performed for 30 minutes per day, 5 days a week, throughout the 3-month study period. To improve patient adherence to exercise, patients will be provided with an exercise diary.
Expérimental: 15 µg Ozone + Exercise
10 mL of ozone injection at a concentration of 15 µg/mL + Home exercise program
Autre: ozone injection
All patients allocated to the ozone intervention groups will receive a total of 3 sessions of intra-articular ozone injections, administered once a week for three consecutive weeks. For all three treatment groups, the injection volume will be 10 mL per session, while the ozone concentrations will vary according to the assigned group as Ozone 10 µg/mL + Exercise, Ozone 15 µg/mL + Exercise, and Ozone 20 µg/mL + Exercise.
Autres noms:
  • Intra-articular Ozone Injection
Comportemental: Exercise

All participants across all four groups will be prescribed a structured home exercise program. This program includes joint range of motion (ROM) exercises; strengthening exercises (including quadriceps strengthening, hamstring strengthening, hip abductor strengthening, and seated calf raises); and flexibility exercises (including hamstring stretching, gastrocnemius-soleus stretching, and quadriceps stretching).

The home program will be performed for 30 minutes per day, 5 days a week, throughout the 3-month study period. To improve patient adherence to exercise, patients will be provided with an exercise diary.
Expérimental: 20 µg Ozone + Exercise
10 mL of ozone injection at a concentration of 20 µg/mL + Home exercise program
Autre: ozone injection
All patients allocated to the ozone intervention groups will receive a total of 3 sessions of intra-articular ozone injections, administered once a week for three consecutive weeks. For all three treatment groups, the injection volume will be 10 mL per session, while the ozone concentrations will vary according to the assigned group as Ozone 10 µg/mL + Exercise, Ozone 15 µg/mL + Exercise, and Ozone 20 µg/mL + Exercise.
Autres noms:
  • Intra-articular Ozone Injection
Comportemental: Exercise

All participants across all four groups will be prescribed a structured home exercise program. This program includes joint range of motion (ROM) exercises; strengthening exercises (including quadriceps strengthening, hamstring strengthening, hip abductor strengthening, and seated calf raises); and flexibility exercises (including hamstring stretching, gastrocnemius-soleus stretching, and quadriceps stretching).

The home program will be performed for 30 minutes per day, 5 days a week, throughout the 3-month study period. To improve patient adherence to exercise, patients will be provided with an exercise diary.
Comparateur actif: Exercise Alone
Home exercise program alone
Comportemental: Exercise

All participants across all four groups will be prescribed a structured home exercise program. This program includes joint range of motion (ROM) exercises; strengthening exercises (including quadriceps strengthening, hamstring strengthening, hip abductor strengthening, and seated calf raises); and flexibility exercises (including hamstring stretching, gastrocnemius-soleus stretching, and quadriceps stretching).

The home program will be performed for 30 minutes per day, 5 days a week, throughout the 3-month study period. To improve patient adherence to exercise, patients will be provided with an exercise diary.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Numerical Rating Scale at Third Month after the last ozone injection
Délai: Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
The Numerical Rating Scale is an 11-point segment scale used to evaluate the severity of knee joint pain. Scores range from 0 to 10, where 0 indicates "no pain" and 10 indicates "the worst possible pain."
Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Knee-specific symptoms and physical function-WOMAC
Délai: Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a self-administered questionnaire specific to knee osteoarthritis, consisting of 24 items divided into 3 subscales: Pain (5 items), Stiffness (2 items), and Physical Function (17 items). Total scores range from 0 to 96, with higher scores indicating worse symptoms and greater physical limitation. Lower scores represent better functional improvement.
Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
Osteoarthritis severity and physical disability- Lequesne Algofunctional Index
Délai: Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
The Lequesne Index is used to assess the severity of knee osteoarthritis and the level of physical disability. It includes questions regarding pain, maximum walking distance, and daily living activities. The total score ranges from 0 to 24. Higher scores indicate more severe osteoarthritis.
Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
Overall health-related quality of life- EuroQol 5-Dimension (EQ-5D) questionnaire
Délai: Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
The EQ-5D questionnaire evaluates general health-related quality of life across 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are converted into an index score ranging from less than 0 to 1. Higher scores indicate a better quality of life.
Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
6-Minute Walk Test (6MWT)
Délai: Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
The 6MWT is an objective clinical test used to assess functional capacity and dynamic mobility. Patients are instructed to walk as far as possible along a straight corridor in 6 minutes. The total distance covered is measured in meters. An increase in the walking distance indicates an improvement in functional mobility.
Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
Timed Up and Go (TUG) Test
Délai: Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.
The TUG test is used to evaluate dynamic balance, mobility, and fall risk. Patients are timed as they rise from a standard chair, walk 3 meters, turn around, walk back to the chair, and sit down. The outcome is recorded in seconds. Shorter completion times represent better balance and mobility.
Baseline, Week 2 (immediately after the 3rd injection session), 1 month after the last ozone injection, and 3 months after the last ozone injection.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Kayseri City Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 novembre 2025

Achèvement primaire (Estimé)

30 novembre 2026

Achèvement de l'étude (Estimé)

30 novembre 2026

Dates d'inscription aux études

Première soumission

16 juin 2026

Première soumission répondant aux critères de contrôle qualité

30 juin 2026

Première publication (Réel)

1 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

30 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • Kayseri-GETAT-2025-102

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner